These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 8841500

  • 1. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R, Vorlicek J, Slavik M.
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [Abstract] [Full Text] [Related]

  • 2. [Paclitaxel (Taxol)].
    Hájek R.
    Cas Lek Cesk; 1996 Jun 12; 135(12):393-6. PubMed ID: 8706079
    [Abstract] [Full Text] [Related]

  • 3. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S, Sekine I, Saijo N.
    Gan To Kagaku Ryoho; 1998 Mar 12; 25(4):605-15. PubMed ID: 9530372
    [Abstract] [Full Text] [Related]

  • 4. The pharmacoeconomics of cancer therapies.
    Bishop JF, Macarounas-Kirchman K.
    Semin Oncol; 1997 Dec 12; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME.
    Can J Oncol; 1996 Jun 12; 6(1):443-57. PubMed ID: 8853517
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
    Gregory RE, DeLisa AF.
    Clin Pharm; 1993 Jun 12; 12(6):401-15. PubMed ID: 7691462
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA, Hartmann LC.
    Semin Oncol; 1996 Oct 12; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel pharmacology and other tumor types.
    Rowinsky EK.
    Semin Oncol; 1997 Dec 12; 24(6 Suppl 19):S19-1-S19-12. PubMed ID: 9427257
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel: current developmental approaches of the National Cancer Institute.
    Arbuck SG.
    Semin Oncol; 1995 Dec 12; 22(6 Suppl 15):55-63. PubMed ID: 8643972
    [Abstract] [Full Text] [Related]

  • 10. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 12; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 11. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P.
    Gynecol Oncol; 1997 Jan 12; 64(1):109-13. PubMed ID: 8995557
    [Abstract] [Full Text] [Related]

  • 12. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H, Guan Z, Lin T.
    Zhonghua Zhong Liu Za Zhi; 1998 Mar 12; 20(2):148-52. PubMed ID: 10920970
    [Abstract] [Full Text] [Related]

  • 13. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Mar 12; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG, Martin T, Kolotas C, Schneider L, Strassmann G, Zamboglou N.
    Semin Oncol; 1997 Aug 12; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [Abstract] [Full Text] [Related]

  • 15. [Paclitaxel].
    Díaz M, Campanero MA.
    Rev Med Univ Navarra; 1996 Aug 12; 40(3):43-51. PubMed ID: 9499826
    [No Abstract] [Full Text] [Related]

  • 16. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Aug 12; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 17. [Evidenced-based medicine and future direction of Taxol].
    Hatae M, Nakamura T, Ohnishi Y.
    Gan To Kagaku Ryoho; 2000 Jul 12; 27(8):1279-87. PubMed ID: 10945027
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley G, Rondinón M, Blajman C, Cóppola FS, Lewi D, Cazap E, Breier S, Fasce H, Fein L, Polera J, Triguboff E, Uranga G, Pasccón G, Luchina AM, Martínez CA, Politi PM, Rubio G, Alvarez AM.
    Semin Oncol; 1997 Oct 12; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [Abstract] [Full Text] [Related]

  • 19. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1996 Dec 12; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA.
    Cancer J; 2000 Dec 12; 6(3):151-6. PubMed ID: 10882330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.